Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Shimizu T, Kawashiri SY, Koga T, Kiya R, Morita M, Kuroda S, Tashiro S, Sato S, Yano H, Asano T, Saito K, Yoshitama T, Ueki Y, Eiraku N, Yamada Y, Okano T, Ushio Y, Dobashi H, Itami T, Tomita D, Nozaki Y, Hosogaya N, Yamamoto H, Kawakami A.
Shimizu T, et al.
Drug Discov Ther. 2025 Sep 17;19(4):253-261. doi: 10.5582/ddt.2025.01044. Epub 2025 Aug 22.
Drug Discov Ther. 2025.
PMID: 40850756
Free article.
Clinical Trial.